Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Association between efavirenz and selected psychiatric and neurological conditions.

Welch KJ, Morse A.

J Infect Dis. 2002 Jan 15;185(2):268-9. No abstract available.

PMID:
11807705
2.

Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects.

Boyd MA, Aarnoutse RE, Ruxrungtham K, Stek M Jr, van Heeswijk RP, Lange JM, Cooper DA, Phanuphak P, Burger DM.

J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):134-9.

PMID:
14526202
3.

Efavirenz-based regimen as treatment of advanced AIDS with cryptococcal meningitis.

Sungkanuparph S, Vibhagool A, Mootsikapun P, Chetchotisakd P, Tansuphaswaswadikul S, Bowonwatanuwong C, Chantratita W.

J Acquir Immune Defic Syndr. 2003 May 1;33(1):118-9. No abstract available.

PMID:
12792366
4.

Clinical history of efavirenz.

Ruiz N.

Int J Clin Pract Suppl. 1999 Jun;103:3-7. Review.

PMID:
10622035
5.

High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients).

Arribas JR, Pulido F, Miró JM, Costa MA, González J, Rubio R, Peña JM, Torralba M, Lonca M, Lorenzo A, Del Palacio A, Vázquez JJ, Gatell JM; EfaVIP Cohort Study Group..

AIDS. 2002 Jul 26;16(11):1554-6.

PMID:
12131195
6.

Efavirenz combination potent after 48 weeks.

[No authors listed]

AIDS Patient Care STDS. 1998 Feb;12(2):145. No abstract available.

PMID:
11361910
7.

Effects on growth after switching protease inhibitors to efavirenz in HIV-1-infected children.

Rosso R, Di Biagio A, Dentone C, Bassetti M, Viscoli C, Parodi A, De Maria A.

Int J Antimicrob Agents. 2007 Feb;29(2):228-30. No abstract available.

PMID:
17196369
8.

Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men.

Reddy YS, Gotzkowsky SK, Eron JJ, Kim JY, Fiske WD, Fiscus SA, Petch L, Cohen MS, Kashuba AD.

J Infect Dis. 2002 Nov 1;186(9):1339-43.

PMID:
12402205
9.

Efavirenz (SUSTIVA) expanded access begins October 1.

James JS.

AIDS Treat News. 1997 Sep 19;(No 279):1-2.

PMID:
11364689
10.

Pharmacokinetics of efavirenz in a patient on maintenance haemodialysis.

Izzedine H, Aymard G, Launay-Vacher V, Hamani A, Deray G.

AIDS. 2000 Mar 31;14(5):618-9. No abstract available.

PMID:
10780727
11.

SSRI safe with efavirenz.

[No authors listed]

AIDS Patient Care STDS. 2000 Dec;14(12):672-3. No abstract available.

PMID:
11187111
12.

Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.

Back DJ, Owen A, Khoo SH.

Clin Pharmacokinet. 2006;45(2):213-4; author reply 214-5. No abstract available.

PMID:
16485918
13.

[Lipodystrophy and antiretroviral agents].

Martínez E, Gatell JM.

Rev Clin Esp. 1999 Aug;199(8):485-6. Spanish. No abstract available.

PMID:
10522426
14.

Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.

Funk MB, Notheis G, Schuster T, Elanjkal Z, von Hentig N, Stürmer M, Linde R, Dunsch D, Königs C, Wintergerst U, Kreuz W.

Eur J Med Res. 2005 Dec 7;10(12):503-8.

PMID:
16356864
15.

DMP 266 now available.

Gilden D.

GMHC Treat Issues. 1997 Sep;11(9):5-6.

PMID:
11364751
16.

Anti-HIV agents. Efavirenz makes its mark in AIDS.

[No authors listed]

TreatmentUpdate. 2002 Aug;14(6):6-7. No abstract available.

PMID:
12238453
17.

Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

López-Cortés LF, Ruiz-Valderas R, Viciana P, Alarcón-González A, Gómez-Mateos J, León-Jimenez E, Sarasanacenta M, López-Pua Y, Pachón J.

Clin Pharmacokinet. 2002;41(9):681-90.

PMID:
12126459
18.

The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.

Veldkamp AI, Harris M, Montaner JS, Moyle G, Gazzard B, Youle M, Johnson M, Kwakkelstein MO, Carlier H, van Leeuwen R, Beijnen JH, Lange JM, Reiss P, Hoetelmans RM.

J Infect Dis. 2001 Jul 1;184(1):37-42.

PMID:
11398107
19.

Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men.

Taylor S, Reynolds H, Sabin CA, Drake SM, White DJ, Back DJ, Pillay D.

AIDS. 2001 Oct 19;15(15):2051-3.

PMID:
11600838
20.

A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.

Wolbach J, Capoccia K.

Nurse Pract. 1999 Jun;24(6):81-2, 87-90, 92. Review. No abstract available.

PMID:
10431297

Supplemental Content

Support Center